Clinical Trial Update: A Study to Determine the Absorption of Peroral Insulin in Dextran Matrix (ORA3) [Phase 1]

View source ↗

Summary

This Phase 1 study assesses the absorption of a peroral insulin formulation in a dextran matrix called ORA3 for diabetes; the trial status is suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus

Drugs mentioned

• ORA3 (peroral insulin in dextran matrix) (insulin)

Snippet

Sponsor: Bows Pharmaceuticals AG | Conditions: Diabetes Mellitus | Phase 1 | Status: SUSPENDED